Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06311578
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-03-08
Brief Title:
A Study of JNJ-87704916 as Monotherapy and in Combination for Advanced Solid Tumors
Sponsor:
Johnson Johnson Enterprise Innovation Inc
Organization:
Johnson Johnson Enterprise Innovation Inc
Study Overview
Official Title:
Phase 1 Study of Intratumoral Administration of JNJ-87704916 an Oncolytic Virus as Monotherapy and in Combination for Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety feasibility recommended doses and regimens of JNJ-87704916 as monotherapy and in combination with cetrelimab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-506495-27-00 | REGISTRY | EUCT number | None |